JANXJanux Therapeutics, Inc.
$16.65-37% 1Y
$16.65
$12.1852 weeks$34.74
Is the price fair?
What JANX's price assumes
Janux Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 40.3× revenue.
40.3
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 1.04
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 1.04
- EV / EBIToperating margin −598%: the multiple describes the denominator
- not meaningful
- Market capitalisation61.1 million shares, counted Aug 4, 2026
- $1.02B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.